【摘要】 目的分析结直肠癌患者血清微小RNA-106b-5p(miR-106b-5p)、miR-30a-5p表达水平与结直肠癌患者预后的关系及其诊断结直肠癌的临床价值。方法选取2013年1月—2014年12月安徽省安庆市第一人民医院肿瘤科手术治疗的结直肠癌患者(结直肠癌组)、门诊确诊的结直肠腺瘤患者(结直肠腺瘤组)和同期健康体检者(健康对照组)作为研究对象,各90例,检测其血清miR-106b-5p、miR-30a-5p表达水平,随访结直肠癌患者的预后情况,并以受试者工作特征曲线(ROC)评估血清miR-106b-5p、miR-30a-5p诊断结直肠癌的价值。结果结直肠癌组血清miR-106b-5p表达水平高于结直肠腺瘤组及健康对照组,血清miR-30a-5p表达水平低于结直肠腺瘤组及健康对照组(F=295.073、374.052,P均=0.000);结直肠癌患者血清miR-106b-5p表达在不同肿瘤直径、淋巴结转移、远处转移及临床分期比较差异有统计学意义(t/P=3.382/0.001、3.130/0.002、3.069/0.003、4.638/0.000),而血清miR-30a-5p表达在不同肿瘤分化程度、浸润深度、淋巴结转移及临床分期比较差异有统计学意义(t/P=3.626/0.000、2.605/0.011、3.265/0.002、3.113/0.002);血清miR-106b-5p高表达亚组、miR-30a-5p低表达亚组患者的术后5年总生存率及中位生存时间均分别低于血清miR-106b-5p低表达亚组、miR-30a-5p高表达亚组(χ~2=11.449,12.613,P均<0.01);ROC分析结果表明,血清miR-106b-5p、miR-30a-5p诊断结直肠癌的AUC为0.785、0.692,敏感度为0.824、0.676,特异度为0.794、0.739,约登指数为0.618、0.415。结论血清miR-106b-5p在结直肠癌患者中升高,血清miR-30a-5p在结直肠癌患者中降低,二者均与不良预后有关,具有作为结直肠癌预后预测和诊断生物标志物的潜能。更多还原

【Abstract】 Objective To analyze the relationship between the expression levels of serum microRNA-106 b-5 p(miR-106 b-5 p) and miR-30 a-5 p in patients with colorectal cancer and the prognosis of patients with colorectal cancer and its clinical value in the diagnosis of colorectal cancer. Methods Selected from January 2013 to December 2014, patients with colorectal cancer(colorectal cancer group), patients with colorectal adenoma(colorectal adenoma group) who were diagnosed in the outpatient department(colorectal adenoma group) and those who were surgically treated in the Department of Oncology, Anqing First People’s Hospital. During the same period, healthy subjects(healthy control group) were taken as the research object, each of 90 cases, their serum miR-106 b-5 p, miR-30 a-5 p expression levels were detected, the prognosis of colorectal cancer patients were followed up, and the receiver operating characteristic curve(ROC) was used. To evaluate the value of serum miR-106 b-5 p and miR-30 a-5 p in the diagnosis of colorectal cancer.Results The expression level of serum miR-106 b-5 p in the colorectal cancer group was higher than that of the colorectal adenoma group and the healthy control group, and the expression level of serum miR-30 a-5 p was lower than that of the colorectal adenoma group and the healthy control group(F=295.073, 374.052, P=0.000); the expression of serum miR-106 b-5 p in patients with colorectal cancer was significantly different in different tumor diameters, lymph node metastasis, distant metastasis and clinical stage(t/P=3.382/0.001,3.130/0.002,3.069/0.003, 4.638/0.000), and serum miR-30 a-5 p expression was significantly different in different tumor differentiation degree, depth of invasion, lymph node metastasis and clinical stage(t/P=3.626/0.000, 2.605/0.011,3.265/0.002, 3.113/0.002); the 5-year overall survival rate and median survival time of patients in the serum miR-106 b-5 p high expression subgroup and miR-30 a-5 p low expression subgroup were lower than those in the serum miR-106 b-5 p low expression subgroup., MiR-30 a-5 p high expression subgroup(χ~2=11.449, 12.613, P<0.01); ROC analysis results showed that serum miR-106 b-5 p, miR-30 a-5 p diagnosed colorectal cancer with AUC of 0.785, 0.692, and sensitivity of 0.824.0.676, specificity is 0.794, 0.739, Youden index is 0.618, 0.415.Conclusion Serum miR-106 b-5 p is elevated in colorectal cancer patients, and serum miR-30 a-5 p is decreased in colorectal cancer patients. Both are related to poor prognosis and have the potential to be a prognostic and diagnostic biomarker of colorectal cancer.更多还原